EPO is a naturally occurring hormone produced by cells in the kidneys that regulate the production of red blood cells in bone marrow.
Increasing incidence of chronic diseases such as end-stage renal diseases, cancer, and HIV is expected to accelerate demand for EPO-stimulating agents as these diseases may cause anemia. To curb rising incidence of anemia, demand for erythropoietin drugs is expected to increase over the coming years.

The global Erythropoietin (EPO) Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Erythropoietin (EPO) Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Erythropoietin (EPO) Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Erythropoietin (EPO) Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Erythropoietin (EPO) Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Amgen
Johnson & Johnson
Roche
Galenica
Emcure
Kyowa Hakko Kirin
3SBio
Biocon
LG Life Sciences

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Epoetin-alfa
Darbepoetin-alfa
Epoetin-beta
Others

Segment by Application
Anemia
Kidney Disorders
Other